Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A meta-analysis of six randomized trials shows [177Lu]Lu‑PSMA significantly increases PSA and objective responses and reduces risk of radiographic progression, with no significant increase in high‑grade toxicity and no clear overall surviva
Interim data from the AlphaBet phase 1/2 trial show that combined 177Lu‑PSMA‑I&T and radium‑223 is feasible, with no dose‑limiting toxicities, a recommended radium‑223 dose of 55.0 kBq/kg, and a PSA50 rate of 55% (95% CI 36–72). Hematol
A phase 1/2 trial demonstrates the safety of [161Tb]Tb-PSMA-I&T, a novel dual beta-Auger radioligand, in heavily pretreated metastatic castration-resistant prostate cancer patients, supporting further clinical investigation.